SCHEMBL3847712

SCHEMBL3847712

Brc1ccc2ncnc(N3CCC(c4ccccc4)CC3)c2c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 6/20 0.61
ALDH1A1 P00352 2/20 0.57
NPSR1 Q6W5P4 2/20 0.57
PDGFRB P09619 1/20 0.51
LMNA P02545 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
PDE3A Q14432 2/20 0.48
IP6K1 Q92551 1/20 0.46
HPGD P15428 3/20 0.44
CYP3A4 P08684 2/20 0.44
HRH1 P35367 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
PRKDC P78527 1/20 0.43
PTK2 Q05397 1/20 0.43
ACHE P22303 1/20 0.43
BACE1 P56817 1/20 0.43
HRH4 Q9H3N8 1/20 0.43
PDE10A Q9Y233 1/20 0.43
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14145462 0.85 LMNA (0.49) HTTALDH1A1LMNASMN1; SMN2PDE3A
SCHEMBL31745385 0.85 HTT (0.57) HTTALDH1A1PDGFRBLMNASMN1; SMN2
SCHEMBL3852113 0.85 HTT (0.58) HTTALDH1A1NPSR1PDGFRBLMNA
SCHEMBL30734240 0.83 HTT (0.56) HTTALDH1A1NPSR1PDGFRBLMNA
SCHEMBL3848130 0.82 HTT (0.71) HTTALDH1A1NPSR1PDGFRBLMNA
SCHEMBL3844439 0.81 SLC2A1 (0.57) HTTALDH1A1NPSR1LMNASMN1; SMN2
SCHEMBL22715242 0.80 HTT (0.76) HTTALDH1A1NPSR1PDGFRBLMNA
SCHEMBL29472072 0.80 HTT (0.76) HTTALDH1A1NPSR1PDGFRBLMNA
SCHEMBL30734218 0.78 CYP3A4 (0.46) ALDH1A1LMNASMN1; SMN2PDE3AHPGD
SCHEMBL3115181 0.78 HTT (0.74) HTTALDH1A1NPSR1PDGFRBLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF UNIV ARIZONA (US) 2025-12-18 US disclosed
EP-2048142-A2 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof Eisai R&D Management Co., Ltd. (JP) 2009-04-15 EP disclosed
EP-2048142-A2 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof Eisai R&D Management Co., Ltd. (JP) 2009-04-15 EP disclosed
EP-1382603-B1 NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF EISAI R&D MAN CO LTD (JP) 2008-07-23 EP disclosed
US-7074801-B1 Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof EISAI CO., LTD. (JP) 2006-07-11 US disclosed
EP-1382603-A1 NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF Eisai Co., Ltd. (JP) 2004-01-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250382301-A1 SMALL MOLECULE INHIBITORS OF DYRK/CLK AND USES THEREOF CLK2, CLK3, CLK1 HTT 713/4885ALDH1A1 4568/4885NPSR1 1834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.